Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704154 | 0.82 | MMP13 (0.39) | ALDH1A1 | |
| SCHEMBL6699473 | 0.77 | MAOB (0.45) | CLPPTP53ALDH1A1 | |
| SCHEMBL6696579 | 0.73 | CLPP (0.33) | CLPPTP53SIGMAR1MAPK14ALDH1A1 | |
| SCHEMBL6700606 | 0.73 | CLPP (0.38) | CLPPTP53SIGMAR1ALDH1A1POLB | |
| SCHEMBL6818720 | 0.73 | PTGER4 (0.50) | TP53 | |
| SCHEMBL6702415 | 0.73 | CLPP (0.33) | CLPPTP53SIGMAR1MAPK14ALDH1A1 | |
| SCHEMBL6818736 | 0.70 | MAPT (0.32) | TP53POLB | |
| SCHEMBL6289380 | 0.69 | SIGMAR1 (0.32) | CLPPSIGMAR1ALDH1A1HTT | |
| SCHEMBL6696585 | 0.69 | CLPP (0.33) | CLPPSIGMAR1ALDH1A1HTT | |
| SCHEMBL6826657 | 0.67 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CLPP 3282/4885TP53 452/4885SIGMAR1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.